Journal
EMBO REPORTS
Volume 15, Issue 3, Pages 244-253Publisher
WILEY
DOI: 10.1002/embr.201338254
Keywords
dedifferentiation; tumor plasticity; somatic reprogramming; cancer stem cells
Categories
Funding
- NIH [HL053670]
- Cancer Center Core Grant [P30 CA014195-38]
- Ipsen
- Leona M. and Harry B. Helmsley Charitable Trust
- H.N. and Frances C. Berger Foundation
Ask authors/readers for more resources
Regenerative medicine aims to replace the lost or damaged cells in the human body through a new source of healthy transplanted cells or by endogenous repair. Although human embryonic stem cells were first thought to be the ideal source for cell therapy and tissue repair in humans, the discovery by Yamanaka and colleagues revolutionized the field. Almost any differentiated cell can be sent back in time to a pluripotency state by expressing the appropriate transcription factors. The process of somatic reprogramming using Yamanaka factors, many of which are oncogenes, offers a glimpse into how cancer stem cells may originate. In this review we discuss the similarities between tumor dedifferentiation and somatic cell reprogramming and how this may pose a risk to the application of this new technology in regenerative medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available